The Liver Meeting: Rectify Pharma presented preclinical data supporting its hypothesis of improving the function of dysfunctional membrane proteins: ABCB4 and BSEP
From Seoul: AimedBio is leveraging patient data and its expertise in antibody discovery and design to develop first-in-class antibody-drug conjugates with unique targets - the first program is FGFR3
London Healthcare Week: Pharvaris is developing an oral bradykinin B2-receptor antagonist for HAE - both in the acute and prophylaxis settings
London Healthcare Week: Rinri Therapeutics is working on a hearing loss solution that uses stems cells that are turned into the precursors of auditory neurons, cells that cannot naturally regenerate
London Healthcare Week: Oculis is aiming to redefine ophthalmology through methods like an eye drop technology that can reach the back of the eye and precision medicine like patient selection
London Healthcare Week: VectorY Therapeutics is delivering antibodies to the CNS using an AAV vector - the first program for ALS is scheduled to go into the clinic next year
From Japan, Takeda's CEO Christophe Weber talks about the company's Japanese roots, but global transformation - plus, five key pipeline assets
Mursla Bio presented data at The Liver Meeting suggesting that its EvoLiver diagnostic test can spot liver cancer among cirrhotic patients with 86% early-stage sensitivity and 88% specificity
London Healthcare Week: The CEO of MoonLake Immunotherapeutics gives an overview of the company's Nanobody platform, including the lead program that targets IL-17A and IL-17F
Sagimet Biosciences presented a subset analysis of the FASCINATE-2 P2 trial of denifanstat in MASH patients at The Liver Meeting showing improved fibrosis based on an AI pathology analysis method
With programs using both somatic cells and iPSCs, and an NK platform for oncology in the works, Japan's Healios aims to be a leader in regenerative medicine
In a post-hoc analysis of 89bio's ENLIVEN phase 2b trial of pegozafermin presented at The Liver Meeting, data suggested that the therapy reduced progression to cirrhosis for MASH patients
An overview of Chugai, including its global ambitions and R&D capabilities, with the company’s CEO, Dr. Osamu Okuda, in Tokyo
Microbiotica is working on microbiome therapies in Cambridge, UK, with lead programs in immuno-oncology and inflammatory bowel disease
Cambridge, UK based Mestag Therapeutics last month announced a license and research collaboration with MSD to leverage the company's fibroblast platform to find inflammatory disease targets
Tokyo based TMS has a lead program that aims to be the first new medicine for acute ischemic stroke in decades
Tokyo based Heartseed is leveraging its expertise iPSCs and regenerative medicine to solve unmet needs in cardiovascular disease like heart failure
SITC 2024: Aulos Bioscience CEO Aron Knickerbocker describes the phase 1 and preliminary phase 2 data for the company's IL-2 redirecting antibody
SITC 2024: Marengo's CEO Zhen Su discusses the first-in-human data for the company's lead program, Invikafusp Alfa
SITC 2024: Compugen's CEO discusses ovarian cancer data for her company's TIGIT + PVRIG + pembro triplet combo
.png){kind=logo}
